Gender differences in the presentation and management of acute coronary syndromes: a national sample of 1365 admissions by Doyle, Frank et al.
Royal College of Surgeons in Ireland
e-publications@RCSI
Psychology Articles Department of Psychology
4-2-2005
Gender differences in the presentation and
management of acute coronary syndromes: a
national sample of 1365 admissions
Frank Doyle
Royal College of Surgeons in Ireland, fdoyle4@rcsi.ie
Davida De La Harpe
Royal College of Surgeons in Ireland
Hannah McGee
Royal College of Surgeons in Ireland
Emer Shelley
Royal College of Surgeons in Ireland
Ronán Conroy
Royal College of Surgeons in Ireland
This Article is brought to you for free and open access by the Department
of Psychology at e-publications@RCSI. It has been accepted for inclusion
in Psychology Articles by an authorized administrator of e-
publications@RCSI. For more information, please contact epubs@rcsi.ie.
Citation
Doyle F, De La Harpe D, McGee H, Shelley E, Conroy R. Gender differences in the presentation and management of acute coronary
syndromes: a national sample of 1365 admissions. European Journal of Cardiovascular Prevention and Rehabilitation
2005;12(4):376-9
— Use Licence —
Attribution-Non-Commercial-ShareAlike 1.0
You are free:
• to copy, distribute, display, and perform the work.
• to make derivative works.
Under the following conditions:
• Attribution — You must give the original author credit.
• Non-Commercial — You may not use this work for commercial purposes.
• Share Alike — If you alter, transform, or build upon this work, you may distribute the resulting work only
under a licence identical to this one.
For any reuse or distribution, you must make clear to others the licence terms of this work. Any of these
conditions can be waived if you get permission from the author.
Your fair use and other rights are in no way affected by the above.
This work is licenced under the Creative Commons Attribution-Non-Commercial-ShareAlike License. To
view a copy of this licence, visit:
URL (human-readable summary):
• http://creativecommons.org/licenses/by-nc-sa/1.0/
URL (legal code):
• http://creativecommons.org/worldwide/uk/translated-license
This article is available at e-publications@RCSI: http://epubs.rcsi.ie/psycholart/6
 1 
Gender differences in the presentation and management of acute coronary 
syndromes: a national sample of 1365 admissions 
Patient gender determines cardiac care 
Frank Doylea,b, Davida De La Harpea, Hannah McGeeb, Emer Shelleya and Ronán 
Conroya 
 
aDepartment of Epidemiology and Public Health Medicine, and bDepartment of 
Psychology, Royal College of Surgeons in Ireland, 123 St. Stephen’s Green, 
Dublin 2, Ireland 
 
Support grant: Funded by a grant from the Department of Health and Children. 
Potential conflict of interest: NONE 
 
Address for correspondence and requests for reprints: 
Frank Doyle 
Health Services Research Centre 
Department of Psychology 
Royal College of Surgeons in Ireland 
Mercer St Lower 
Dublin 2 
Ireland 
Tel: +353 1 4022718, Fax: +353 1 4022329, Email: fdoyle4@rcsi.ie 
 
Word count:  2941 
 2 
Background Gender differences in presentation and management of acute 
coronary syndromes (ACS) are well established internationally. This study 
investigated differences in a national Irish sample. 
Design Cross-sectional survey. 
Methods All centres (N=39) admitting cardiac patients to intensive/coronary care 
provided information on 25 consecutive acute myocardial infarction patients and 
other ACS patients admitted concurrently (N=1365 episodes). Patient data was 
analysed in terms of those with prior ACS/revascularisation, and those without. 
Results Men with prior established ACS/revascularisation were twice as likely to 
have received revascularisation procedures (coronary artery bypass graft or 
percutaneous coronary intervention) prior to admission when controlling for age, 
total cholesterol and insurance status (OR 1.97, 95% CI 1.18-3.29, p=0.011). No 
gender differences were seen in acute-phase reperfusion (OR 0.96, 95% CI 0.76-
1.24, p>0.05) or anti-platelet therapy (OR 0.99, 95% CI 0.69-1.41, p>0.05). For 
patients with prior ACS/revascularisation, men were twice as likely to receive 
statins on discharge after adjustment for age and total cholesterol (OR 1.94, 95% 
CI 1.02-3.71, p=0.045). 
Conclusions Women were treated differently to men. Fewer women with a 
positive history of ACS received revascularisation prior to current admission and 
fewer women were prescribed lipid-lowering medications on discharge. Acute 
phase hospital treatment was not gender determined. These findings have 
implications for secondary prevention in Ireland. 
Key words Acute coronary syndrome; acute myocardial infarction; gender; Ireland; 
revascularisation 
Abstract word count: 219 
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Introduction 
Gender differences in the presentation and management of acute coronary 
syndromes (ACS) are well established internationally [1-3]. Previous research has 
reported that women present with different symptomatology and may subsequently 
be diagnosed differently [1;4]. Women admitted for ACS also have lower rates of 
prior revascularisation, both bypass surgery and percutaneous coronary 
intervention (PCI) [2;5]. During the acute phase of hospitalisation, there is evidence 
that women receive less reperfusion therapy [1]. The medications prescribed on 
discharge may vary by gender. The Euro Heart Survey of ACS demonstrated that 
women were less likely to receive anti-platelets, beta-blockers and statins on 
discharge, but more likely to receive diuretic medication [3]. 
 
Little is known about the current gender profile of treatment of ACS in Ireland. This 
study analysed gender differences in the presentation and management of a 
national cohort of suspected ACS patients admitted to intensive or coronary care 
units in all 39 Republic of Ireland hospitals providing such care. 
 
Method 
Sample/Participants 
Hospitals 
All Irish centres admitting suspected acute myocardial infarction patients to 
intensive/coronary care units (I/CCU) were invited and agreed to participate in the 
survey (N=39). Ethics committee approval was obtained from individual 
centres/areas as appropriate [6]. Data were collected in 2003. 
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Participants and Procedure 
Suspected ACS patients admitted to intensive/coronary care were recruited. This 
included patients with an admission diagnosis of either acute myocardial infarction 
or unstable angina. All relevant staff were supplied with the consensus definition of 
ACS, which uses enzyme change as a marker for necrosis [7]. Participating 
hospitals audited hospital charts of all consecutive suspected ACS patients, until 
25 suspected cases of acute myocardial infarction had been admitted to 
intensive/coronary care. A total of 1365 episodes were recruited for this survey 
(935 suspected acute myocardial infarction and 430 contemporaneously admitted 
suspected other ACS). Data were collected on demographic and past clinical 
history, risk factors, admission details, acute treatments given and discharge 
status. Data were also collected on time to treatment, and data collectors 
approached eligible patients for consent to participate in a follow-up survey (results 
reported separately). 
 
Statistical analysis 
Data were analysed using robust variance estimation methods with STATA/SE 8.0 
to account for the clustering of patients within hospitals. Patients were grouped into 
two broad categories: those with a prior positive history of ACS or revascularisation 
(acute myocardial infarction, unstable angina or previous coronary artery bypass 
surgery or PCI – ACS/revascularisation group) (39%), and those without (61%). 
Logistic regression was conducted on each group to determine odds ratios (OR) 
for each event. Control variables were gender, age, having private insurance, and 
total cholesterol. Insurance was originally analysed as completely private cover, 
 5 
State-provided secondary care cover, or State-provided primary and secondary 
care cover. However, Wald test analysis after logistic regression determined that 
both State-provided insurance groups were similar, and insurance was 
subsequently analysed as a dichotomous variable (i.e. having private health 
insurance or not). Due to significant gender differences in age, all data was age-
adjusted, and data presented in tables was adjusted to age 65 years (to portray a 
‘typical’ coronary patient). 
 
Results 
Baseline characteristics 
Of the 1365 suspected ACS episodes, 386 (28%) were women. Mean age for men 
on intensive/coronary care admission was 63 years (std dev=13; range 20-100). 
Mean age for women, at 69 years (std dev=13, range 23-94) was significantly 
higher than that of men (t=8.7, p<.001). Baseline characteristics of the sample are 
shown in Table 1.  
 
________________ 
Table 1 about here 
________________ 
 
A higher total cholesterol (OR=1.30, 95% CI 1.12-1.51) and older age of admission 
(OR=1.03, 95% CI 1.02-1.05) were significant predictors of being admitted with 
suspected acute myocardial infarction as opposed to other ACS for men, but only 
age (OR=1.04, 95% CI 1.02-1.06) was a significant predictor of suspected acute 
myocardial infarction for women.  
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In terms of past history, women had a higher prevalence of hypertension (49% vs. 
37%), lower prevalence of any type of coronary heart disease (38% vs. 45%), 
lower prevalence of prior acute myocardial infarction or prior ACS (14% vs. 23% 
and 33% vs. 39% respectively), and lower rates of prior revascularisation (10% vs. 
19%)(i.e. significantly lower levels of bypass surgery (4% vs. 9%) and PCI (6% vs. 
11%)). Overall, women were less likely to have established prior 
ACS/revascularisation (33% vs. 41%), and were less likely to be taking anti-platelet 
medication on index admission (34% vs. 44%). 
 
Although women had a significantly lower prevalence of prior ACS, this did not 
account for all the variation in prevalence of prior revascularisation (PCI or bypass 
surgery). Using data from patients with prior ACS/revascularisation (39%), a 
logistic regression model showed that the odds of having had revascularisation 
prior to the current admission were statistically related to gender, age, private 
insurance status and total cholesterol level. Men with a history of 
ACS/revascularisation were almost twice as likely as women to have had a 
previous revascularisation when controlling for these other variables (OR 1.97, 
95% CI 1.18-3.29, p=0.011). For every year increase in age, a 4% decrease in the 
likelihood of having prior revascularisation was seen (OR 0.96, 95% CI 0.93-0.98, 
p=0.001). For every mmol/l unit increase in total cholesterol patients were 27% less 
likely to have had revascularisation (OR 0.73, 95% CI  0.58-0.93, p=0.011). 
Patients with private health insurance were over twice as likely to receive 
revascularisation than those without (OR=2.02, 95% CI 1.29-3.19, p=0.003). 
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Results were similar when data for all invasive cardiac procedures were analysed 
(data not shown). 
 
Overall, no gender differences were seen for prior anti-hypertensive medication 
use (OR 0.95, 95% CI 0.71-1.3, p>0.05) or for prior statin prescription (OR 1.18, 
95% CI 0.93-1.48, p>0.05). For patients with prior ACS/revascularisation this 
finding was repeated: no differences for anti-hypertensive medication use (OR 
1.03, 95% CI 0.61-1.74, p>0.05) or statin use (OR 1.02, 95% CI 0.69-1.49, p>0.05) 
by gender were seen on index admission. 
 
Process of care and discharge details 
The process of care received by gender is shown in Table 2. 
 
_______________ 
Table 2 about here 
_______________ 
 
No gender differences were seen in acute-phase reperfusion (thrombolysis or 
direct PCI) (OR 0.96, 95% CI 0.76-1.24, p>0.05) or acute anti-platelet therapy (OR 
0.99, 95% CI 0.69-1.41, p>0.05). 
 
There was no gender difference in age-adjusted mortality rates (OR 0.85, 95% CI 
0.59-1.24, p>0.05). Similar percentages of men and women were discharged on 
anti-platelet (OR 1.11, 95% CI 0.8-1.54, p>0.05) and anti-hypertensive medications 
(OR 1.09, 95% CI 0.76-1.57, p>0.05). There were however gender differences for 
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lipid-lowering medication. The odds of being prescribed statins were 34% higher 
for men when controlling for age (OR 1.34, 95% CI 1.03-1.72, p=0.027), and 35% 
higher when controlling for both age and total cholesterol (OR 1.35, 95% CI 1.01-
1.81, p=0.043). Translating these findings into a clinical example: a 65 year old 
woman with a total cholesterol level of 5 mmol/l had a 76% chance of being 
prescribed a statin on intensive/coronary care discharge. A man of the same age 
and cholesterol level had an 81% (a 5% higher) chance of being prescribed a statin 
on discharge. 
 
Even women with prior ACS/revascularisation were also less likely to be prescribed 
statins on intensive/coronary care discharge than men with prior 
ACS/revascularisation, when controlling for age and total cholesterol level 
(OR=1.94, 95% CI 1.02-3.71, p=0.045). For a patient aged 65 with a total 
cholesterol level of 5 mmol/l, this translated to an 86% chance a man would be 
prescribed statins, but only a 77% chance that a woman would be. However, 
women without prior ACS/revascularisation on admission were just as likely to 
receive statins on discharge as were men with no past history, when controlling for 
age and total cholesterol level (OR=1.09, 95% CI 0.75-1.6, p>0.05). 
 
Discussion 
The present survey evaluated the treatment of suspected ACS patients on a 
national level. It highlighted that men and women were treated differently in certain 
key aspects of care. Differences in treatments received by gender were seen both 
before the current hospitalisation in patients with prior established coronary 
disease, and at discharge. 
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The first major finding in the current survey was that women with prior history of 
ACS/revascularisation were less likely to have received revascularisation prior to 
index admission. Men were almost twice as likely to have had prior 
revascularisation when controlling for age, private insurance status and total 
cholesterol level.  Indeed, men were also almost twice as likely as women to have 
had any form of invasive cardiac treatment (data not shown). Differential treatment 
by gender occurred when deciding whether a patient should undergo invasive 
cardiac treatment, even though the patients had already previously entered the 
healthcare system. This data replicates international findings on prevalence of 
revascularisation rates between men and women [2-5;8;9]. It may be that the 
women in the present survey did not require revascularisation, as their underlying 
disease could differ significantly from their male counterparts [1;4]. Therefore, 
although women received differing levels of treatment, it may not have been 
suboptimal. However, this seems unlikely as data from those with a confirmed 
positive history of ACS/revascularisation were analysed. Older patients were also 
less likely to have received revascularisation. 
 
In terms of prescribed medications, there were no differences between genders in 
the rate of anti-hypertensive or lipid-lowering medication prescription prior to the 
current admission. This parity was also reflected in the acute care of patients, with 
similar numbers of men and women receiving both reperfusion therapy and anti-
platelet therapy during the current admission. This finding compares well against 
other surveys which have shown that women receive less acute reperfusion 
therapy than men [1;10]. 
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On intensive/coronary care discharge, similar proportions of men and women were 
prescribed anti-platelet and anti-hypertensive medications (although women 
received more diuretic medications). The levels prescribed compare well with the 
Euro Heart Survey [3]. However, women were significantly less likely to be 
prescribed lipid-lowering medications. For patients aged 65 with a total cholesterol 
level of 5.0 mmol/l, this translated into a 5% decreased chance of being prescribed 
statins for women. This reflects a significant disadvantage for women in secondary 
prevention. Given that lipid-lowering therapy reduces coronary heart disease 
mortality for women [11], and that it is recommended that all coronary heart 
disease patients be prescribed lipid-lowering medication regardless of total 
cholesterol level [12], this finding is of concern. Interestingly, for those who had no 
prior ACS/revascularisation, women were just as likely as men to be prescribed 
statins. The differential treatment was only seen for women with a prior history of 
ACS/revascularisation. Reasons for this are unknown, and this aspect requires 
further research. 
 
In relation to gender, the present results show that some aspects of international 
guidelines are being adhered to (in this case reperfusion guidelines), whereas 
other aspects (statin prescription) have yet to be fully implemented. These findings, 
along with the findings of other similar research, where discrepancies in treatments 
between genders are seen [1-5;8-10], need to be further discussed by Cardiology 
Societies at national and international level. 
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Conclusions 
Overall, there is evidence of treatment bias in favour of men in this national sample 
of patients admitted to intensive/coronary care for suspected ACS. This is reflected 
in increased coronary interventions in men prior to the current acute admission, 
and in a higher rate of prescription of lipid-lowering medication on 
intensive/coronary care discharge. Encouragingly, there were no treatment 
differences in the acute phase of in-hospital treatment, with men and women 
receiving reperfusion and anti-platelet medications equally often. The extent to 
which these findings reflect differing onset patterns of coronary heart disease for 
men and women needs to be further investigated. 
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Table 1: Baseline characteristics of sample (age-adjusted to 65 years) (% unless 
otherwise stated) 
 Male 
(N=979) 
Female 
(N=386) 
Total 
(N=1365) 
Percentage of sample 72 28*** 100 
Mean Age= - years (standard deviation) 63 (13) 69 (13)*** 64 (13) 
Suspected acute myocardial infarction 68 71 69 
Private insurance 33 29 31 
Previous risk factor history 
   
Positive family history of coronary heart disease 41 46 43 
Any prior history of coronary heart disease 45 38* 43 
Hypertension 37 49*** 40 
Established prior ACS/revascularisation 41 33** 39 
History of acute coronary syndrome (ACS) 39 33* 37 
Acute myocardial infarction 23 14** 20 
Unstable angina 18 18 18 
Any prior invasive cardiac treatment 19 10*** 16 
Revascularisation 18 9** 15 
Percutaneous coronary intervention 11 6* 10 
Bypass surgery 9 4** 7 
Diabetes: Type I 3 4 4 
  Type II 10 9 10 
Total cholesterol= (mmol/l) (mean) 4.8 5.0 4.9 
Previous cardiovascular medications (%) 
   
Aspirin/anti-platelets 44 34* 41 
Antihypertensives 45 46 45 
ACE inhibitors 24 22 24 
Beta-blockers 27 23 26 
Calcium antagonists 6 10* 7 
Diuretics 6 9 7 
Statins 28 25 27 
*p<0.05, **p<0.01, ***p<0.001; =, no age-adjustment; ACS, acute coronary syndrome; ACE, angiotensin 
converting enzyme 
 
 
 15 
Table 2: In-hospital process of care by gender for total sample (age-adjusted to 65 
years) (%) 
 
Male Female Total 
Acute treatments (%) 
   
Aspirin/other anti-platelets 78 79 78 
Reperfusion 30 32 30 
I/CCU discharge cardiovascular medications= 
   
Aspirin/anti-platelets 91 90 91 
Anithypertensives 89 88 89 
Beta-blockers 70 67 69 
ACE inhibitors 57 58 57 
Diuretics 11 16** 12 
Calcium antagonists 4 6 5 
Statins 79 73* 77 
I/CCU Discharge diagnoses 
   
Acute myocardial infarction 67 72 69 
Unstable angina 19 14 17 
Other cardiac 16 16 16 
Non-cardiac 7 8 7 
Mortality 4 5 4 
*p<0.05, **p<0.01, ***p<0.001; =, for patients discharged from hospital alive; I/CCU, intensive/coronary 
care unit; ACE, angiotensin converting enzyme 
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